D Ajona1,2, M J Pajares1,2,3, M D Chiara4, J P Rodrigo4, E Jantus-Lewintre5,6, C Camps7,8, C Suarez4, J V Bagán9, L M Montuenga1,2,3, R Pio1,2,10. 1. Program in Solid Tumors and Biomarkers, Center for Applied Medical Research (CIMA), Pamplona, Spain. 2. Navarra's Health Research Institute (IDISNA), Pamplona, Spain. 3. Department of Histology and Pathology, School of Medicine, University of Navarra, Pamplona, Spain. 4. Servicio de Otorrinolaringología, Hospital Universitario Central de Asturias, Instituto Universitario de Oncología del Principado de Asturias, Universidad de Oviedo, Oviedo, Spain. 5. Molecular Oncology Laboratory, Fundación para la Investigación del Hospital General Universitario de Valencia, Valencia, Spain. 6. Department of Biotechnology, Universitat Politècnica de Valencia, Valencia, Spain. 7. Department of Medicine, University of Valencia, Valencia, Spain. 8. Department of Medical Oncology, Hospital General Universitario de Valencia, Valencia, Spain. 9. Department of Oral Medicine, University of Valencia, and Service of Stomatology and Maxillofacial Surgery, University General Hospital, Valencia, Spain. 10. Department of Biochemistry and Genetics, School of Sciences, University of Navarra, Pamplona, Spain.
Abstract
OBJECTIVE: Complement C4d-containing fragments have been proposed as diagnostic markers for lung cancer. The purpose of this study was to evaluate the presence of C4d in oropharyngeal (OPSCC) and oral (OSCC) squamous cell carcinomas. SUBJECTS AND METHODS: C4d staining was analyzed by immunohistochemistry in 244 OPSCC surgical specimens. C4d levels were quantified by ELISA in resting saliva samples from 48 patients with oral leukoplakia and 62 with OSCC. Plasma samples from 21 patients with leukoplakia and 30 with oral carcinoma were also studied. RESULTS: C4d staining in OPSCC specimens was associated with nodal invasion (P = 0.001), histopathologic grade (P = 0.014), disease stage (P = 0.040), and focal-adhesion kinase expression (P < 0.001). No association was found between C4d and prognosis. Saliva C4d levels were higher in patients with oral cancer than in subjects with leukoplakia (0.07 ± 0.07 vs 0.04 ± 0.03 μg ml(-1) , P = 0.003). The area under the ROC curve was 0.63 (95%CI: 0.55-0.71). Salivary C4d levels in stage IV patients were higher than in patients with earlier stages (P = 0.028) and correlated with tumor size (P = 0.045). Plasma C4d levels also correlated with salivary C4d levels (P = 0.041), but differences between patients with oral cancer and subjects with leukoplakia were not significant (1.26 ± 0.59 vs 1.09 ± 0.39 μg ml(-1) , P = 0.232). CONCLUSION: C4d-containing fragments are detected in oral primary tumors and are increased in saliva from patients with OSCC.
OBJECTIVE: Complement C4d-containing fragments have been proposed as diagnostic markers for lung cancer. The purpose of this study was to evaluate the presence of C4d in oropharyngeal (OPSCC) and oral (OSCC) squamous cell carcinomas. SUBJECTS AND METHODS: C4d staining was analyzed by immunohistochemistry in 244 OPSCC surgical specimens. C4d levels were quantified by ELISA in resting saliva samples from 48 patients with oral leukoplakia and 62 with OSCC. Plasma samples from 21 patients with leukoplakia and 30 with oral carcinoma were also studied. RESULTS: C4d staining in OPSCC specimens was associated with nodal invasion (P = 0.001), histopathologic grade (P = 0.014), disease stage (P = 0.040), and focal-adhesion kinase expression (P < 0.001). No association was found between C4d and prognosis. Saliva C4d levels were higher in patients with oral cancer than in subjects with leukoplakia (0.07 ± 0.07 vs 0.04 ± 0.03 μg ml(-1) , P = 0.003). The area under the ROC curve was 0.63 (95%CI: 0.55-0.71). Salivary C4d levels in stage IV patients were higher than in patients with earlier stages (P = 0.028) and correlated with tumor size (P = 0.045). Plasma C4d levels also correlated with salivary C4d levels (P = 0.041), but differences between patients with oral cancer and subjects with leukoplakia were not significant (1.26 ± 0.59 vs 1.09 ± 0.39 μg ml(-1) , P = 0.232). CONCLUSION: C4d-containing fragments are detected in oral primary tumors and are increased in saliva from patients with OSCC.
Authors: Martin Kolev; Madhumita Das; Monica Gerber; Scott Baver; Pascal Deschatelets; Maciej M Markiewski Journal: Front Immunol Date: 2022-07-01 Impact factor: 8.786
Authors: Thomas Klikovits; Paul Stockhammer; Viktoria Laszlo; Yawen Dong; Mir Alireza Hoda; Bahil Ghanim; Isabelle Opitz; Thomas Frauenfelder; Thi Dan Linh Nguyen-Kim; Walter Weder; Walter Berger; Michael Grusch; Clemens Aigner; Walter Klepetko; Balazs Dome; Ferenc Renyi-Vamos; Rudolf Oehler; Balazs Hegedus Journal: Sci Rep Date: 2017-11-28 Impact factor: 4.379
Authors: Daniel Ajona; Marcin Okrój; María J Pajares; Jackeline Agorreta; María D Lozano; Javier J Zulueta; Carla Verri; Luca Roz; Gabriella Sozzi; Ugo Pastorino; Pierre P Massion; Luis M Montuenga; Anna M Blom; Ruben Pio Journal: Oncotarget Date: 2017-12-26
Authors: Alejandro I Lorenzo-Pouso; Mario Pérez-Sayáns; Susana B Bravo; Pía López-Jornet; María García-Vence; Manuela Alonso-Sampedro; Javier Carballo; Abel García-García Journal: Dis Markers Date: 2018-11-07 Impact factor: 3.434
Authors: Ruben Pio; Daniel Ajona; Sergio Ortiz-Espinosa; Alberto Mantovani; John D Lambris Journal: Front Immunol Date: 2019-04-12 Impact factor: 7.561